Discrepancies in widely used serological methods to detect *Borrelia* infections may cause missed Lyme diagnoses

Elena Volokhina[1]*, Annette Stemerding[2], Yesper Smits[1], Jordi Lankhof[1], Milou Kouwijzer[1], Anja Garritsen[1].

[1]Innatoss Laboratories B.V., Oss, The Netherlands; [2]Deventer Hospital, Deventer, the Netherlands

*Corresponding author:

Elena Volokhina, PhD,

elena.volokhina@innatoss.com

Wethouder van Eschstraat 44, 5342 AT Oss, The Netherlands.

Tel: +31 412 700507

Samples

All blood/serum samples and data reported in this article were submitted to Innatoss for diagnostic purposes. The Medisch Ethische Toetsingscommissie Brabant, Tilburg, the Netherlands has waived the need for IRB approval of reuse of surplus diagnostics materials (NW2020-77). The sample/patient IDs cannot be used to reveal identity of the study subjects, and they are not known to anyone outside the research group.

Acknowledgements

We thank Mats van Kempen for technical support and Willemijn Anker and Saskia Theunisse for organizational support for this work.

Conflict of interest

AG is a senior officer and shareholder, and EV, YS, JL and MK are employees of Innatoss Laboratories B.V., which provides diagnostic screening for infectious diseases including *Borrelia* infections.

Abstract

The accurate diagnosis of Lyme disease, caused by *Borrelia burgdorferi*, is critical for effective treatment and prevention of disabling long-term effects. This study investigates discrepancies in serological testing methods for *Borrelia* infections, focusing on the performance of different assays in annual Lyme screening for high-risk populations. We compared the results of two-tier protocols, including first-tier assays from EUROIMMUN, ZEUS, SERION (all ELISA) and Diasorin (CLIA). Our findings reveal significant variability in test sensitivity: EUROIMMUN combined with ZEUS ELISA detected more positive cases compared to the Diasorin and SERION tests. Notably, 19% of recent *Borrelia* infections were missed due to test selection, highlighting the clinical implications of these discrepancies. Case studies illustrate the potential for misdiagnosis and delayed treatment, emphasizing the need for standardized and optimized testing protocols. We recommend the adoption of more sensitive and comprehensive methods, and the practice of comparing current results with previous samples from the same individual to improve diagnostic accuracy and patient outcomes.

Key words: *Borrelia*, Lyme disease, antibodies, method, sensitivity

Introduction

Lyme disease is caused by bacteria of the *Borrelia burgdorferi sensu lato* species. Most cases in Europe are caused by *B. afzelii* or *B. garinii* and in the USA and Canada by *B. burgdorferi sensu stricto* (1, 2).

Antibodies against *Borrelia* in Europe are more prevalent in groups with higher exposure to ticks than in the general population (3), which underscores higher rates of *Borrelia* infection in these groups. Moreover, Lyme disease is recognized by the Dutch government as an occupational hazard for outdoor workers in forestry, gardening, landscape and wild-life management, agriculture and other areas (4).

Diagnosis of Lyme disease relies on the history of tick bites and clinical symptoms. However, missed *Borrelia* infections occur frequently. Only 25-73% of Lyme disease patients recall having a tick bite (5). Erythema migrans (EM), the earliest symptom of Lyme borreliosis, is not noticed in approximately 20% of cases, which therefore remain untreated and may progress to Lyme arthritis (60%), Lyme neuroborreliosis (15%) and Lyme carditis (5%) (2, 5-8). To protect high-risk groups, regular screening for *Borrelia* antibodies allows detection of missed infections, timely start of antibiotic treatment and prevention of further complications. Innatoss Laboratories performs an annual Lyme screening for individuals with high occupational exposure to ticks. Screening is done in colder months (October–February), when ticks are not or less active.

An important drawback of any serological testing is the inability to distinguish between antibodies produced during recent infection, which still requires treatment, and an already cleared infection in the past. Therefore, in the annual Lyme screening performed by Innatoss, positive results are always compared with the previous measurement of the same subject. An increase in one or more enzyme-linked immunosorbent assay (ELISA) values, supported by changes in an immunoblot is considered a strong indication of a *B. burgdorferi* infection acquired since the previous measurement.

The annual Lyme screening is performed according to the two-tier testing algorithm, which consists in tier one of the EUROIMMUN Anti-*Borrelia* plus VlsE ELISA (IgG) and EUROIMMUN Anti-*Borrelia* ELISA (IgM). Additionally, the ZEUS *Borrelia* VlsE1/pepC10 IgG/IgM ELISA is used (8, 9). The ZEUS test contains VlsE and contributes to recognition of this important antigen (10-12). If one or more ELISA tests in tier one is positive, *Borrelia* ViraStripe® IgG and/or IgM immunoblot by Viramed Biotech AG is performed to confirm the presence of antibodies.

There are multiple CE-marked serological tests for Lyme disease. Recently, three individuals were tested positive for *Borrelia* antibodies in the annual Lyme screening, while found negative or inconclusive in other laboratories that use different Lyme tests. To investigate the possible cause of discrepancy, the performance of these tests was compared in the samples of these subjects and in a larger cohort.

Results

Two initial cases with discrepant results

Two adults (case 1 and case 2) had no detectable *Borrelia* antibodies in the first years that they participated in the annual Lyme screening. In November 2023 (case 1) and January 2024 (case 2), the ELISA values increased, confirmed by the immunoblot (Figure 1). Both participants were referred to a general practitioner (GP). Both GPs repeated testing at different laboratories. In both cases, the IgG and IgM tests ordered by a GP were negative and no antibiotic treatment for Lyme disease was prescribed.

In case 1, samples were exchanged with the laboratory that performed the testing for the GP. This laboratory uses Diasorin chemiluminescence immunoassays (CLIA) for *Borrelia* serology: LIAISON Borrelia IgG and LIAISON Borrelia IgM Quant. The samples taken in November 2023 and January 2024 showed an increase in EUROIMMUN IgG and ZEUS VlsE1/pepC10 IgG/IgM ELISA of Innatoss (Figure 1A), which was confirmed by the immunoblot (Figure 1C). These samples were negative in the IgG and IgM CLIA of the GP's laboratory.

In case 2, the analyses ordered by GP were done using SERION IgG and IgM ELISAs. It was not possible to exchange samples for this case. Therefore, the SERION ELISA *classic* Borrelia burgdorferi IgG and IgM tests were implemented at Innatoss to perform the analyses. In the sample from Januari 2024, the SERION IgG and IgM ELISA results were negative, while the EUROIMMUN IgG and ZEUS VlsE1/pepC10 IgG/IgM ELISA showed an increase in antibodies (Figure 1B), which was confirmed by the immunoblot (Figure 1D).

Borrelia infections in a set of samples

To study how often discrepancies between the tests occur and lead to missed Lyme diagnoses, a selection of samples available from the annual Lyme screening cohort was tested. This cohort consists of a high-risk population of over 5000 participants. The prevalence of *Borrelia* antibodies in this group was 15-25% in the period of 2016-2024, while reported prevalence for the general population in the Netherlands between 2016-2017 was only 4.4% (13).

From this cohort, 21 individuals were selected that were negative before March 2021, but had antibodies in the annual Lyme screening that started in October 2021, indicating a recent *Borrelia* infection (Table 1). The follow-up samples were taken between October 2021 and March 2022.

All samples were tested according to the Innatoss annual Lyme screening protocol. Additionally, the tests were performed by Innatoss in the SERION IgG and IgM ELISA and by MVZ Dr. Stein + Kollegen (Mönchengladbach) in the Diasorin IgG and IgM CLIA, as used in case 1. The samples of four participants showed discrepant results in tier one (Table 1). P3709 showed positive results in the EUROIMMUN IgM ELISA and equivocal results in the Diasorin IgM CLIA but negative results in the SERION IgM ELISA. P3749 and P4726 were positive in both the EUROIMMUN IgM and SERION IgM ELISA, but negative in the Diasorin IgM CLIA. P4548 yielded positive results in the EUROIMMUN IgG ELISA and ZEUS VlsE1/pepC10 IgG/IgM ELISA but was negative in SERION IgG ELISA and Diasorin IgG CLIA. All positive results were confirmed by antigen bands on the corresponding immunoblot (Table 1). Thus, four out of 21 (19%) *Borrelia* infections could have been missed due to the choice of the test. Such

discrepancies have important clinical implications, as they may lead to misdiagnosis of Lyme disease and delayed treatment.

This is illustrated by case 3. A teenage patient with fatigue, joint pain and headache which may be indicative of Lyme borreliosis was referred to the hospital. As part of the differential diagnosis, Lyme serology using the Diasorin CLIA as tier one test was performed in two samples taken five weeks apart. In both samples, the IgG CLIA test was negative, and the IgM CLIA test was positive, but not confirmed in the recomLine Borrelia IgM immunoblot (Mikrogen Diagnostik). When the same samples were tested at Innatoss, the results were positive in EUROIMMUN IgG and IgM ELISA and ZEUS VlsE1/pepC10 ELISA. Viramed IgG immunoblots were negative, but IgM antibodies were confirmed by a positive OspC antigen band (Figure 3), supporting a diagnosis of Lyme disease. The patient received a doxycycline treatment (200 mg/day, 28 days), after which the symptoms were relieved.

Discussion

The results show that the two-tier Lyme testing, which includes the EUROIMMUN IgG and IgM ELISA and ZEUS *Borrelia* VlsE1/pepC10 IgG/IgM ELISA, detected more positive cases compared to protocols using the Diasorin CLIA and the SERION IgG and IgM ELISA. The observed discrepancies are consistent with previous reports indicating variability in serological test performance for Lyme disease (14-16). The meta-analysis of 78 studies reported a 50% sensitivity for EM (95% CI: 40% to 61%); 77% for neuroborreliosis (95% CI: 67% to 85%); 97% for acrodermatitis chronica atrophicans (95% CI: 94% to 99%) and 73% for unspecified Lyme borreliosis (95% CI: 53% to 87%) (14). Sensitivity of serological methods is higher in the more advanced stages of the disease. Unfortunately, so are the damaging effects for the patients. Improvement of diagnostics of early borreliosis is therefore extremely important.

Nevertheless, alternatives to the serological testing in Lyme disease are limited and their performances are disappointing. The recent VICTORY study evaluated performance of the three cellular tests for borreliosis and demonstrated that they all have lower specificity than the serological tests, which increases the chance of false-positive outcomes (17). The direct detection of Borrelia is challenging due to the low number of bacteria present during infection. The nucleic acid amplification tests have sensitivity of only 30-50 % in blood of EM patients. When performed on EM biopsies, sensitivity may reach 50-80% however, about 20% of patients do not report EM and thus cannot be diagnosed in this way (2, 5, 8).

To date, serological testing is the most reliable method to detect exposure to *Borrelia*, however, choice of the test and testing strategy are important. The discrepancies between different serological tests can lead to missed diagnoses of Lyme disease, as illustrated by the three cases in this study. Misdiagnosis not only may affect a patient's health and quality of life but also increase healthcare costs due to the need for more intensive treatments in later stages of the disease (6, 7).

Therefore, it is crucial for healthcare providers to be aware of the limitations and strengths of different testing protocols. The use of more sensitive and comprehensive testing methods, such as a broader two-tier protocol including an additional ELISA as used by Innatoss, should be considered to ensure accurate diagnosis and timely treatment.

In 2024, an INSTAND report on external quality assessment for *Borrelia* serology indicated that 42% of the participating laboratories use the Diasorin CLIA; 6% use a SERION ELISA; 26% use

the EUROIMMUN ELISAs; data for the ZEUS ELISA are not available (18). Wide-spread use of the Diasorin CLIA can be explained by automation, efficiency and cost-effectiveness of the LIAISON platform, making it attractive, especially for high-volume laboratories. Unfortunately, use of this platform for *Borrelia* serology may lead to missed Lyme diagnoses.

The source of discrepancies between tests is not clear. The lesser sensitivity is likely due to the difference in strains and antigens that are used in the tests (Table 2). EUROIMMUN and SERION use antigens from different strains to coat ELISA wells, ZEUS wells are coated with VlsE1 and pepC10 peptide and Diasorin test uses recombinant OspC and/or VlsE proteins. However, other factors, such as antigen concentration, sequence and conformation may also affect assay sensitivity. Next to discrepancies in tier one tests, tier two immunoblots may also produce different results, as illustrated in case 3. The difference in sensitivity between immunoblots may also be explained by differences in design of the tests (Table 2). Multiple antigens in Viramed and Mikrogen blots are different or target different strains (for example OspC and p41 in IgM and IgG blots).

Future efforts should be directed to further standardization of Lyme serological testing. An international standard, containing relevant antigens should be developed to allow for careful quantification of antibodies in samples, as are available for antibodies to other infectious pathogens, such as *Coxiella burnetii* and SARS-CoV-2 (19, 20).

In addition, interpretation of a single VlsE antigen band on IgG immunoblot should be reevaluated. Currently such blots are interpreted as equivocal, however, if such results are perceived as negative, infections may be missed. This is illustrated by case 2 of this manuscript, where the increase in both the EUROIMMUN IgG and the ZEUS ELISA is accompanied by appearance of only the VlsE antigen band on the immunoblot (Figure 1B and D). In early stages of disease understanding the dynamics of Borrelia-specific antibodies is the key to successful use of serology.

In conclusion, our results underscore the importance of serological testing as well as the critical need for standardization and optimization of Lyme disease testing protocols. The use of more comprehensive and sensitive methods, such as the protocol used by Innatoss, should be strongly considered to improve diagnostic accuracy and patient outcomes. Importantly, consensus on the relevance of key antigens such as VlsE should be reached, so interpretation of different immunoblots can be harmonized. Furthermore, the practice of comparing current results to previous samples from the same individual should be more widely implemented in routine serological screening for Lyme disease of high-risk groups.

Figure 1. Serological analyses of the serum samples of the two initial cases. Dates of collection are shown as month and year. **A** and **B.** EUROIMMUN IgG and IgM (left Y-axis) and ZEUS VlsE1/pepC10 IgG/IgM (right Y-axis) ELISA results. The cut-offs for positive values are indicated by solid (EUROIMMUN IgG and IgM) and broken (ZEUS VlsE1/pepC10) red lines. RU/mL stands for relative units per milliliter. All results from Diasorin CLIA (case 1) and SERION ELISA (case 2) tests were negative and are not shown. **C** and **D.** Viramed IgG immunoblot results. Positions of negative (neg), positive (pos) and conjugate (IgG) controls; cut-off and separation line (sep) are indicated above the upper strip. Location of the VlsE antigen band is indicated by the red boxes. Overall conclusions per strip are indicated on the left.



Figure 2. Serological analysis of four subjects that showed an increase in antibodies since the previous measurement in EUROIMMUN IgM, IgG (left Y-axis) or ZEUS VlsE1/pepC10 (right Y-axis) ELISA tests, but were negative in Diasorin CLIA or SERION ELISA tests (see Table 1). The cut-offs for positive values are indicated by solid (EUROIMMUN IgG and IgM) and broken (ZEUS VlsE1/pepC10) red lines. RU/mL stands for relative units per milliliter. Positive values are confirmed by immunoblot (Table 1).



Figure 3. Serological analyses of the serum samples of case 3. Dates of collection are shown as month and year. **A.** EUROIMMUN IgG and IgM (left Y-axis) and ZEUS VlsE1/pepC10 IgG/IgM (right Y-axis) ELISA results. The cut-offs for positive values are indicated by solid (IgG and IgM) and broken (VlsE1/pepC10) red lines. RU/mL stands for relative units per milliliter. Results from CLIA IgM were positive (31 AU/mL (May-24) and 23 AU/mL (Jun-24)) and CLIA IgG were negative for both samples (not shown). **B**. Viramed IgM immunoblot results. Positions of negative (neg), positive (pos) and conjugate (IgM) controls; cut-off and separation line (sep) are indicated above the upper strip. Location of OspC antigen band is indicated by red box. Overall conclusions per strip are indicated on the left. Results of the Mikrogen IgG and IgM immunoblots were negative in both samples (not shown).



Table 1. Samples of the participants of the Lyme screening with a recent *Borrelia* infection. Diasorin CLIA tests were performed at MVZ Dr. Stein + Kollegen (Mönchengladbach), all other tests were done at Innatoss. Positive results are marked by gray color and equivocal results are framed.

		Tier one							Tier two	
Person	**Sample**	**EUROIMMUN IgG**	**SERION IgG**	**Diasorin IgG**	**ZEUS IgG/IgM**	**EUROIMMUN IgM**	**SERION IgM**	**Diasorin IgM**	**Viramed IgG**	**Viramed IgM**
P902	Oct-21	5.9	1.0	0	1.3	111.8	19.4	142.9	N/A	OspC, p41
P2217	Mar-22	15.8	3.9	0	0.9	238.5	37.9	126.3	no bands	OspC
P83	Nov-21	251.8	100.0	1288	5.1	107.7	17.8	41.9	OspC, p14, p39, p43, VlsE	OspC, p41
P835	Dec-21	7.0	1.0	0	1.9	28.4	13.7	42	no bands	OspC, p41
P4797	Dec-21	7.1	1.0	0	0.2	25.2	5.1	24.8	no bands	OspC
P1683	Nov-21	3.1	1.0	0	1.0	161.4	33.7	190	N/A	OspC, p41
P2626	Nov-21	19.7	1.0	0	1.6	93.8	9.7	28	no bands	OspC
P3709*	Oct-21	3.6	1.0	0	0.6	37.2	1.0	18.3	N/A	OspC
P3749*	Oct-21	4.3	1.0	0	0.5	27.6	5.8	14.5	N/A	OspC, p41
P300	Jan-22	2.3	2.0	0	0.2	141.6	35.6	190	N/A	OspC
P3234	Jan-22	5.7	1.0	0	0.5	91.8	14.0	39.3	N/A	OspC
P1872	Nov-21	77.5	16.2	36.3	1.5	6.0	1.3	0	Osp17, VlsE	N/A
P847	Dec-21	5.2	1.0	0	0.6	43.5	10.4	19.5	N/A	OspC, p41
P504	Oct-21	7.7	1.0	0	0.8	193.0	22.3	75.4	N/A	OspC, p41
P2837	Oct-21	130.3	18.1	52.9	2.5	10.9	1.5	5.4	p14, VlsE	N/A
P4796	Jan-22	65.5	13.3	11.3	1.2	5.4	1.0	0	Osp17, VlsE	no bands
P2795	Jan-22	8.1	1.2	0	0.4	116.2	11.2	60.1	N/A	OspC
P2794	Oct-21	30.0	9.6	18.4	1.5	4.4	2.0	4	p30, p43, VlsE	N/A
P4548*	Jan-22	29.2	1.0	0	2.1	8.3	1.3	5.7	no bands	Osp17
P1824	Jan-22	4.8	1.0	0	0.4	106.3	12.0	24.1	N/A	OspC
P4726*	Dec-21	5.1	1.0	0	0.5	27.2	6.5	13.2	N/A	OspC

*Samples with discrepant ELISA results, see also Figure 2.
N/A: not available immunoblots (not done because tier one tests were negative).

Table 2. Serological tests that are used in this manuscript. Strain information is given as specified by the manufacturer.

Assay	**Method**	**Antigens**
EUROIMMUN IgG	ELISA	Whole cell extract (Bbss, Ba, Bg) and recombinant VlsE (Bbss)
SERION IgG	ELISA	Whole cell extract (Ba, Bg) and recombinant VlsE (Bg)
Diasorin IgG	CLIA	Recombinant VlsE*
EUROIMMUN IgM	ELISA	Whole cell extract (Bbss, Ba, Bg)
SERION IgM	ELISA	Whole cell extract (Ba,Bg)
Diasorin IgM	CLIA	Recombinant OspC and VlsE*
ZEUS IgG/IgM	ELISA	Recombinant VlsE1, pepC10 (peptide of OspC)*
Viramed IgG	Immunoblot	Purified native: OspC (Bbss), p22 (Bbss), Osp17 (Ba), DbpA (Bbss), p14 (Ba) Recombinant: p83 (Ba, Bbss), p58 (Bbss), p43 (Ba), p39 (Bbss), p30 (Bbss), VlsE (Ba, Bbss, Bbav, Bg, Bs)
Mikrogen IgG	Immunoblot	Recombinant: OspC (Bbss, Ba, Bg, Bs), p41 (Bbss), p100 (Ba), p58 (Bg), p39 (Ba), OspA (Ba), p18 (Bbss, Ba, Bg, Bs, Bbav), VlsE (different genospecies)
Viramed IgM	Immunoblot	Purified native: OspC (Bbss), p41(Bbss) Recombinant: p39 (Bbss), Osp17 (Ba), VlsE (Bbss, Ba, Bg)
Mikrogen IgM	Immunoblot	Same as Mikrogen IgG

*Strain of sequence origin is not specified

Bbss (*B. burgdorferi sensu stricto*), Ba (*B. afzelii*), Bg (*B. garinii*), Bbav (*B. bavariensis*), Bs (B*. spielmanii*)

References

1. Marques AR, Strle F, Wormser GP. Comparison of Lyme Disease in the United States and Europe. Emerg Infect Dis. 2021;27(8):2017-24.
2. Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090.
3. Burn L, Pilz A, Vyse A, Gutiérrez Rabá AV, Angulo FJ, Tran TMP, et al. Seroprevalence of Lyme Borreliosis in Europe: Results from a Systematic Literature Review (2005-2020). Vector Borne Zoonotic Dis. 2023;23(4):195-220.
4. Achtergronddocument Bij registratierichtlijn C005 Ziekte van Lyme als beroepsziekte, CAS-code A432. Nederlands Centrum voor Beroepsziekten; 2016.
5. Stanek G, Strle F. Lyme borreliosis-from tick bite to diagnosis and treatment. FEMS Microbiol Rev. 2018;42(3):233-58.
6. Pavia CS, Saggio G, Plummer MM. The major epidemiologic, microbiologic, immunologic, and clinical aspects of Lyme disease that form the basis for a newly developed vaccine that may become available soon for human use. Front Immunol. 2023;14:1326623.
7. Hatchette TF, Davis I, Johnston BL. Lyme disease: clinical diagnosis and treatment. Can Commun Dis Rep. 2014;40(11):194-208.
8. Branda JA, Steere AC. Laboratory Diagnosis of Lyme Borreliosis. Clin Microbiol Rev. 2021;34(2).
9. (CDC) CfDCaP. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995;44(31):590-1.
10. Baarsma ME, Vrijlandt A, Ursinus J, Zaaijer HL, Jurriaans S, van Dam AP, et al. Diagnostic performance of the ZEUS Borrelia VlsE1/pepC10 assay in European LB patients: a case-control study. Eur J Clin Microbiol Infect Dis. 2022;41(3):387-93.
11. Eicken C, Sharma V, Klabunde T, Lawrenz MB, Hardham JM, Norris SJ, et al. Crystal structure of Lyme disease variable surface antigen VlsE of Borrelia burgdorferi. J Biol Chem. 2002;277(24):21691-6.
12. Wozinska M, Toczylowski K, Lewandowski D, Bojkiewicz E, Milewski R, Sulik A. Diagnostic Precision in Lyme borreliosis: Assessing VlsE and C6 Antigens in a Pediatric Cohort. Diagnostics (Basel). 2023;13(23).
13. Hoeve-Bakker BJA, van den Berg OE, Doppenberg HS, van der Klis FRM, van den Wijngaard CC, Kluytmans JAJW, et al. Seroprevalence and Risk Factors of Lyme Borreliosis in The Netherlands: A Population-Based Cross-Sectional Study. Microorganisms. 2023;11(4).
14. Leeflang MM, Ang CW, Berkhout J, Bijlmer HA, Van Bortel W, Brandenburg AH, et al. The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:140.
15. Hoeve-Bakker BJA, Jonker M, Brandenburg AH, den Reijer PM, Stelma FF, van Dam AP, et al. The Performance of Nine Commercial Serological Screening Assays for the Diagnosis of Lyme Borreliosis: a Multicenter Modified Two-Gate Design Study. Microbiol Spectr. 2022;10(2):e0051022.
16. Lager M, Dessau RB, Wilhelmsson P, Nyman D, Jensen GF, Matussek A, et al. Serological diagnostics of Lyme borreliosis: comparison of assays in twelve clinical laboratories in Northern Europe. Eur J Clin Microbiol Infect Dis. 2019;38(10):1933-45.
17. Baarsma ME, van de Schoor FR, Gauw SA, Vrijmoeth HD, Ursinus J, Goudriaan N, et al. Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study. Lancet Infect Dis. 2022;22(9):1388-96.
18. INSTAND certification documents 202403. INSTAND; 2024.

19. Infantino M, Pieri M, Nuccetelli M, Grossi V, Lari B, Tomassetti F, et al. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. Int Immunopharmacol. 2021;100:108095.
20. Organization WH. International collaborative study to evaluate and establish the 1st WHO Reference Reagent for Anti-Q fever Phases I and II IgG human plasma. WHO/BS/2023.2456. 2023.